Q3 2012

Filed Nov 29, 2012 · 10-Q · 60 days after period end · 0001469709-12-000341

Q3 2012 · 10-Q

Revenue

$7.16K

no prior Q3 2011 on file

Net Income

-$392.90K

no prior Q3 2011 on file

EPS Diluted

-$0.01

no prior Q3 2011 on file

Operating Income-$372,640—

Operating Cash Flow

Same quarter

no prior Q3 2011 on file

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

ended Sep 30, 2012 · filed Nov 29, 2012 · 60 d after period end

Endonovo Therapeutics, Inc. · CIK 1528172 · Engraved from SEC EDGAR